pharmacopeia

Acne vulgaris

Diseases of the skin and subcutaneous tissue

ICD-10 L70.017 drugs
GET
/api/v1/condition/acne-vulgaris
Reference index only. Each drug below carries an FDA-labeled indication that maps to L70.0 via a conservative crosswalk. This is not a treatment recommendation, a formulary, or a statement that any listed drug is appropriate for any patient — and the crosswalk is deliberately precision-biased, so absence does not mean a drug is not indicated.

Drugs labeled for Acne vulgaris (17)

  • Adapalene
    • Use For the treatment of acne
  • Ammonium Bromide
    • Acne, pimples, rashes.
  • Benzoyl Peroxide
    • Uses For the treatment and management of acne Penetrates pores to eliminate most acne and blemishes Helps prevent development of new acne blemishes and blackheads
  • Clascoterone
    • WINLEVI (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. WINLEVI (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
  • Clindamycin
    • Clindamycin phosphate topical lotion is indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate (see CONTRAINDICATIONS , WARNINGS and ADVERSE REACTIONS ).
  • Erythromycin
    • Erythromycin Topical Solution USP, 2% is indicated for the topical treatment of acne vulgaris.
  • Iodoquinol
    • Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: “Possibly” Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation.
  • Isotretinoin
    • Severe Recalcitrant Nodular Acne Isotretinoin capsules are indicated for the treatment of severe recalcitrant nodular acne. Nodules are inflammatory lesions with a diameter of 5 mm or greater.
  • Loteprednol
    • Loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%.
  • Loteprednol Etabonate
    • Loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%.
  • Salicylic Acid
    • Use for the treatment of acne
  • Sarecycline
    • SEYSARA ® (sarecycline) tablet, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Limitations of Use Efficacy of SEYSARA beyond 12 weeks and safety beyond 12 months have not been established.
  • Silver
    • for Use For the relief of these symptoms due to minor wounds and burns, bruises, ulcerations, sunburn, razor burn, scrapes, rashes, blisters, bug bites, and skin eruptions from acne, eczema, or minor infection: • burning • stinging • itching • redness • stiffness • minor pain • minor inflammation
  • Sodium Bromide
    • Acne, pimples, rashes.
  • Sulfur
    • Uses Helps clear up acne blemishes and helps prevent new acne blemishes from forming.
  • Tazarotene
    • TAZORAC ® Cream 0.05% and 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis. ( 1.1 ) TAZORAC Cream 0.1% is indicated for the topical treatment of acne vulgaris.
  • Trifarotene
    • AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

Conditions most often co-labeled across the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.

Note. Conditions map FDA-labeled indications to ICD-10-CM concepts. Listing a drug under a condition reflects a labeled use only — it is NOT a treatment recommendation, formulary, or clinical guidance.

Search pharmacopeia

Search drugs, classes, and ingredients